AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11866264 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study 10752774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term glucose infusion of 25 g in 30 min
Number of subjects: 26
Study 10752774 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose infusion of 10 g/h
Number of subjects: 26
Study 8638536 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intraarterial infusion chemotherapy with 25 mg/m2 of cisplatin and 15 mg/m2 of bleomycin via each internal iliac artery.
Number of subjects: 50
Study 8638536 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving radiation therapy (external irradiation and intracavitary irradiation).
Number of subjects: 50
Study 1309493 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal sepsis (Group 2)
Number of subjects: 17
Study 6533162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracarotid urokinase injections
Number of subjects: 2
Study 31169130 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 31169130 — intervention group
Group type: EXPERIMENTAL
Intervention: Age strata
Number of subjects: 0
Study 31169130 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and Age
Number of subjects: 0
Study 28806208 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 40
Study 28806208 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol
Number of subjects: 40
Study 28806208 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 40
Study 27312912 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 20
Study 27312912 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 20
Study 25252032 — intervention group
Group type: EXPERIMENTAL
Intervention: 150kg/person of rice from non-KBD areas
Number of subjects: 280
Study 25252032 — intervention group
Group type: EXPERIMENTAL
Intervention: 7kg/family of selenium-iodine salt
Number of subjects: 280
Study 25252032 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 280
Study 22659373 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin alone (40 mg/day)
Number of subjects: 30
Study 22659373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin combined therapy (10/20 or 10/40 mg/day)
Number of subjects: 30
Study 22659373 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated patients (including both interventions)
Number of subjects: 30
Study 20481650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 75 mg alone
Number of subjects: 12
Study 20481650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg after 4 days of ritonavir 100 mg once daily
Number of subjects: 12
Study 20481650 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir treatment
Number of subjects: 12
Study 18588757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation (daily until 6 months after RT)
Number of subjects: 107
Study 18588757 — intervention group
Group type: COMPARATOR
Intervention: Nonirrigation (no nasal irrigation after RT)
Number of subjects: 107
Study 15911819 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-frequency repetitive transcranial magnetic stimulation (rTMS) to the unaffected hemisphere
Number of subjects: 0
Study 15911819 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 0
Study 12431355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A (Edmonston-Zagreb, Leningrad-Zagreb, RA 27/3 strains)
Number of subjects: 10142
Study 12431355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B (Moraten, Jeryl Lynn, Wistar 27/3 strains)
Number of subjects: 10142
Study 12431355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine C (Schwartz, Urabe AM-9, Wistar 27/3 strains)
Number of subjects: 10142
Study 12431355 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 10142
Study 10507269 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.25 mg, 0.50 mg, or 1.0 mg)
Number of subjects: 359
Study 10507269 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.50 mg and 1.0 mg)
Number of subjects: 359
Study 10507269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 8951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided prostate biopsy
Number of subjects: 170
Study 31918984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE) with 10% evening basal insulin reduction
Number of subjects: 12
Study 31918984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE) with 20% evening basal insulin reduction
Number of subjects: 12
Study 31918984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE) with 30% evening basal insulin reduction
Number of subjects: 12
Study 31918984 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Number of subjects: 12
Study 31918984 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control day
Number of subjects: 12
Study 31358401 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-blue irradiation treatment
Number of subjects: 118
Study 31358401 — intervention group
Group type: COMPARATOR
Intervention: White-light irradiation (Control)
Number of subjects: 118
Study 27416005 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised slackline training (EG)
Number of subjects: 22
Study 27416005 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 25333776 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily for 26 weeks
Number of subjects: 100
Study 25333776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23345636 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder taping and conventional treatment
Number of subjects: 162
Study 23345636 — intervention group
Group type: COMPARATOR
Intervention: Sham taping and conventional treatment
Number of subjects: 162
Study 21886365 — intervention group
Group type: EXPERIMENTAL
Intervention: auto‐CPAP for 2 nights and continued for 30 days for those with sleep apnea
Number of subjects: 55
Study 21886365 — intervention group
Group type: EXPERIMENTAL
Intervention: auto‐CPAP use
Number of subjects: 55
Study 21886365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auto‐CPAP)
Number of subjects: 55
Study 18715634 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified IMCI guidelines implemented after September 2004
Number of subjects: 1532
Study 15900287 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldenseal
Number of subjects: 12
Study 15900287 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava Kava
Number of subjects: 12
Study 15900287 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Cohosh
Number of subjects: 12
Study 15900287 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 12
Study 12859140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin; specific dosage and duration not mentioned.
Number of subjects: 0
Study 11113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyretic therapy (nonsteroidal anti-inflammatory drugs)
Number of subjects: 0
Study 11113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyretic therapy
Number of subjects: 0
Study 9139620 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 30
Study 1642652 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 212
Study 1642652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (AZA + MTX)
Number of subjects: 212
Study 1642652 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 212
Study 6430063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 300 mg t.i.d.
Number of subjects: 85
Study 6430063 — intervention group
Group type: COMPARATOR
Intervention: No lithium (Control)
Number of subjects: 85
Study 31731611 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting Intervention (six home visits by a trained Youth Health Care nurse during the first 18 months)
Number of subjects: 301
Study 31731611 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 301
Study 31731611 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting Intervention
Number of subjects: 301
Study 30076573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic notifications to primary care physicians
Number of subjects: 2336
Study 30076573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2336
Study 27220523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet PC questionnaire
Number of subjects: 178
Study 27220523 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire
Number of subjects: 178
Study 27220523 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 178
Study 27220523 — intervention group
Group type: COMPARATOR
Intervention: Both methods (tablet PC and paper)
Number of subjects: 178
Study 22830517 — intervention group
Group type: EXPERIMENTAL
Intervention: LT peel (lidocaine 70 mg/g and tetracaine 70 mg/g)
Number of subjects: 110
Study 22830517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (SunLase™ 800) - two-minute group
Number of subjects: 64
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (SunLase™ 800) - one-minute group
Number of subjects: 64
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma® desensitizer
Number of subjects: 64
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure Quick®
Number of subjects: 64
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quell™ desensitizer
Number of subjects: 64
Study 22313266 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSens®
Number of subjects: 64
Study 22313266 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated dentin surface)
Number of subjects: 64
Study 20586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapies (thrombolytic therapy)
Number of subjects: 95
Study 18247267 — intervention group
Group type: EXPERIMENTAL
Intervention: Job-related programme (intervention group)
Number of subjects: 300
Study 18247267 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation interventions (control group)
Number of subjects: 300
Study 16221898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12608943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment at a dose of 10 mg/day for 12 months
Number of subjects: 68
Study 10509846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg on day 1, 200 mg daily on days 2‐4)
Number of subjects: 88
Study 10509846 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg BID)
Number of subjects: 88
Study 10509846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sparfloxacin and terfenadine
Number of subjects: 88
Study 10509846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 8605132 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 143
Study 8605132 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 143
Study 1940190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA, Supralox, 1 tablet three times a day 1 h a.c. and 2 tablets at bedtime, with acid binding capacity of 225 mEq)
Number of subjects: 100
Study 1940190 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MS, Cytotec, 400 micrograms p.o. b.i.d.)
Number of subjects: 100
Study 1940190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA)
Number of subjects: 100
Study 1940190 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MS)
Number of subjects: 100
Study 6757394 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-site (WS) treatment program
Number of subjects: 100
Study 6757394 — intervention group
Group type: COMPARATOR
Intervention: Regular care (RC)
Number of subjects: 100
Study 29516455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolphin Assisted Therapy (DAT)
Number of subjects: 44
Study 29516455 — intervention group
Group type: COMPARATOR
Intervention: Therapeutical Intervention Without Dolphins (TIWD)
Number of subjects: 44
Study 27343343 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based upper limb training program for 8 weeks, twice a week
Number of subjects: 37
Study 27343343 — intervention group
Group type: COMPARATOR
Intervention: Control group received information in the form of a leaflet with a schedule of upper limb exercise training
Number of subjects: 37
Study 25350855 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based tool for management of postoperative complications
Number of subjects: 20
Study 25350855 — intervention group
Group type: COMPARATOR
Intervention: No checklist
Number of subjects: 20
Study 22307144 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐promotion intervention (7-session program, 2 hours per session)
Number of subjects: 73
Study 22307144 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐promotion intervention
Number of subjects: 73
Study 22307144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 20925565 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehome monitoring device
Number of subjects: 0
Study 18589766 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxinqing tablet
Number of subjects: 66
Study 18589766 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxinqing tablet + half dose Simvastatin
Number of subjects: 66
Study 18589766 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose Simvastatin
Number of subjects: 66
Study 12760517 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization with fluent speech containing words that fit phonological patterns
Number of subjects: 0
Study 12760517 — intervention group
Group type: COMPARATOR
Intervention: Familiarization with fluent speech containing words that violated phonological patterns
Number of subjects: 0
Study 10509040 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus STNI (supradiaphragmatic radiotherapy and para-aortic irradiation)
Number of subjects: 73
Study 10509040 — intervention group
Group type: COMPARATOR
Intervention: STNI (supradiaphragmatic radiotherapy and para-aortic irradiation)
Number of subjects: 73
Study 10509040 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus STNI
Number of subjects: 73
Study 10509040 — intervention group
Group type: COMPARATOR
Intervention: STNI
Number of subjects: 73
Study 8903493 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 0
Study 8903493 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study 1863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal calcitonin (400 iu)
Number of subjects: 0
Study 1863827 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6666645 — intervention group
Group type: EXPERIMENTAL
Intervention: nomifensine 25-50 mg taken three times daily
Number of subjects: 57
Study 6666645 — intervention group
Group type: COMPARATOR
Intervention: Motipress (1.5 mg fluphenazine with 30 mg nortriptyline) taken once daily
Number of subjects: 57
Study 29952695 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE training
Number of subjects: 40
Study 29625095 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back risk group (low, medium, high)
Number of subjects: 1109
Study 29625095 — intervention group
Group type: COMPARATOR
Intervention: Medium-risk group
Number of subjects: 1109
Study 29625095 — intervention group
Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 1109
Study 27932449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 200 mg twice daily
Number of subjects: 88
Study 26594629 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis of autistic participants solving RSPM problems
Number of subjects: 0
Study 26594629 — intervention group
Group type: COMPARATOR
Intervention: fMRI analysis of non-autistic participants solving RSPM problems
Number of subjects: 0
Study 26594629 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological interaction analyses (PPI) in autistic participants
Number of subjects: 0
Study 26594629 — intervention group
Group type: COMPARATOR
Intervention: PPI analyses in non-autistic participants
Number of subjects: 0
Study 23440726 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded pursuers
Number of subjects: 0
Study 23440726 — intervention group
Group type: COMPARATOR
Intervention: Sighted pursuers
Number of subjects: 0
Study 21719364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 21719364 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (IG)
Number of subjects: 0
Study 19090898 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin lock six times a week
Number of subjects: 30
Study 19090898 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock three times a week
Number of subjects: 30
Study 16542788 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) with radiation therapy (RT)
Number of subjects: 214
Study 16542788 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiation therapy (RT)
Number of subjects: 214
Study 12669013 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 0
Study 12669013 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 10727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max) in premenarcheal girls
Number of subjects: 41
Study 10727072 — intervention group
Group type: COMPARATOR
Intervention: Maximal oxygen uptake (VO2max) in young adult women
Number of subjects: 41
Study 10727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric scaling of VO2max
Number of subjects: 41
Study 10727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Average maximal cardiac output
Number of subjects: 41
Study 10727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal stroke volume
Number of subjects: 41
Study 9101194 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C
Number of subjects: 48
Study 9101194 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy (Control)
Number of subjects: 48
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTCA)
Number of subjects: 432
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 432
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CABG and PTCA
Number of subjects: 432
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG or PTCA
Number of subjects: 432
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG or PTCA in younger cohort
Number of subjects: 432
Study 7963199 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG or PTCA in older cohort
Number of subjects: 432
Study 3790403 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg biphasic release tablet of nifedipine
Number of subjects: 0
Study 27832062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise protocol (free weight exercises intercalating aerobic exercise)
Number of subjects: 3
Study 27832062 — intervention group
Group type: COMPARATOR
Intervention: Free weight exercises
Number of subjects: 3
Study 27832062 — intervention group
Group type: COMPARATOR
Intervention: Machine exercises
Number of subjects: 3
Study 27832062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise protocol
Number of subjects: 3
Study 27832062 — intervention group
Group type: COMPARATOR
Intervention: Machine and free weight protocols
Number of subjects: 3
Study 26501506 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention about the usefulness of AD biomarkers (n = 119)
Number of subjects: 219
Study 26501506 — intervention group
Group type: COMPARATOR
Intervention: Placebo group reading general information about the ADRC (n = 100)
Number of subjects: 219
Study 26501506 — intervention group
Group type: EXPERIMENTAL
Intervention: General public sample (n = 1418)
Number of subjects: 219
Study 22437967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level fluence 810 nm (15 Joules/cm(2)) laser diode therapy
Number of subjects: 17
Study 22437967 — intervention group
Group type: COMPARATOR
Intervention: Nontreated shaved control areas
Number of subjects: 17
Study 20356626 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years program (16 weeks, group format)
Number of subjects: 35
Study 20356626 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control group)
Number of subjects: 35
Study 18373036 — intervention group
Group type: EXPERIMENTAL
Intervention: PLASA intervention group
Number of subjects: 1120
Study 18373036 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1120
Study 15853819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with PTU (100 mg twice a day), propranolol (40 mg twice a day), and cholestyramine (4 g twice a day) for 4 weeks
Number of subjects: 30
Study 15853819 — intervention group
Group type: COMPARATOR
Intervention: PTU (100 mg twice a day) and propranolol (40 mg twice a day) for 4 weeks
Number of subjects: 30
Study 12456913 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 26
Study 12456913 — intervention group
Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 26
Study 10713872 — intervention group
Group type: COMPARATOR
Intervention: N2O (20, 40, 60, and 70% inhaled at 20-min intervals)
Number of subjects: 14
Study 10713872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg kg‐1 + 1.0 mg kg‐1h‐1)
Number of subjects: 14
Study 7547843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 31